PACIFIC SHUANGLIN BIO-PHARMACY CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30 CNY | +0.67% |
|
+5.97% | +10.13% |
| Apr. 15 | Pacific Shuanglin Bio-pharmacy's 2023 Profit Jumps 4% Despite Lower Revenue; Shares Rise 4% | MT |
| Apr. 15 | Pacific Shuanglin Bio-pharmacy's Profit Seen More Than Doubling in Q1; Shares Up 3% | MT |
| Sales 2023 * | 2.3B 317M | Sales 2024 * | 2.94B 406M | Capitalization | 21.98B 3.04B |
|---|---|---|---|---|---|
| Net income 2023 * | 556M 76.8M | Net income 2024 * | 713M 98.48M | EV / Sales 2023 | - |
| Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 7.47 x |
| P/E ratio 2023 * |
39.6
x | P/E ratio 2024 * |
30.8
x | Employees | 2,093 |
| Yield 2023 * |
0.23% | Yield 2024 * |
0.33% | Free-Float | 50.8% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.67% | ||
| 1 week | +5.97% | ||
| Current month | +6.61% | ||
| 1 month | +7.07% | ||
| 3 months | +20.39% | ||
| 6 months | +41.18% | ||
| Current year | +10.13% |
1 week
28.05
30.64
1 month
26.8830.64
Current year
21.2130.64
1 year
17.4931.25
3 years
16.2038.96
5 years
13.0950.31
10 years
8.9050.31
| Managers | Title | Age | Since |
|---|---|---|---|
Ye Hong Wang
DFI | Director of Finance/CFO | 33 | 21-03-25 |
Xiao Ying Huang
BRD | Director/Board Member | 50 | 23-10-24 |
Yu Lin Zhao
SEC | Corporate Secretary | 37 | 19-05-20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jun Yin
BRD | Director/Board Member | 69 | 23-10-24 |
Jin Gang Zhang
BRD | Director/Board Member | 61 | Dec. 10 |
Shao Lan Fu
CHM | Chairman | 82 | Dec. 10 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +1.25% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 30 | +0.67% | 4,762,053 |
| 24-04-18 | 29.8 | +1.09% | 4,779,871 |
| 24-04-17 | 29.48 | -0.64% | 4,582,786 |
| 24-04-16 | 29.67 | +0.27% | 5,716,696 |
| 24-04-15 | 29.59 | +4.52% | 6,908,211 |
End-of-day quote Shenzhen S.E., April 18, 2024
More quotes
Pacific Shuanglin Bio pharmacy Co Ltd, formerly Southern Shuanglin Bio-pharmacy Co Ltd, formerly Zhenxing Biopharmaceutical & Chemical Co., Ltd., is a China-based company mainly engaged in the research, development, production and sales of blood products. The Company's main products are human albumin, intravenous immunoglobulin (pH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus immunoglobulin and rabies immunoglobulin. The Company mainly operates its business in the domestic market.
Sector
Pharmaceuticals
Calendar
2024-04-26
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
30
CNY
Average target price
25.94
CNY
Spread / Average Target
-13.53%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +10.13% | 3.02B | |
| -5.99% | 84.46B | |
| +2.76% | 40.85B | |
| -24.88% | 27.69B | |
| +53.61% | 24.28B | |
| -8.08% | 17.09B | |
| -33.74% | 13.67B | |
| -16.63% | 11.86B | |
| -11.19% | 11.79B | |
| -2.25% | 8.07B |
- Stock Market
- Equities
- 000403 Stock
